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Abstract (words 245) 1 
 2 
Background: Advanced glycation endproducts (AGE) and their receptor (RAGE) have been 3 
implicated in cancer development through their pro-inflammatory capabilities. However, 4 
prospective data on their association with cancer of specific sites, including pancreatic 5 
cancer, are limited. 6 
Methods: Pre-diagnostic blood levels of the AGE product Nε-(carboxymethyl)lysine (CML) 7 
and the endogenous secreted receptor for AGE (esRAGE) were measured using ELISA in 8 
454 exocrine pancreatic cancer patients and individually matched controls within the 9 
European Prospective Investigation into Cancer and Nutrition (EPIC). Pancreatic cancer risk 10 
was estimated by calculating odds ratios (OR) with corresponding 95% confidence intervals 11 
(CI). 12 
Results: Elevated CML levels tended to be associated with a reduction in pancreatic cancer 13 
risk (OR = 0.57 [95% CI 0.32-1.01] comparing highest with lowest quintile), whereas no 14 
association was observed for esRAGE (OR = 0.98 [95% CI 0.62-1.54]). Adjustments for BMI 15 
and smoking attenuated the inverse associations of CML with pancreatic cancer risk (OR = 16 
0.78 [95% CI 0.41-1.49]). There was an inverse association between esRAGE and risk of 17 
pancreatic cancer for cases that were diagnosed within the first two years of follow-up (OR = 18 
0.46 [95% CI 0.22-0.96] for a doubling in concentration), whereas there was no association 19 
among those with a longer follow-up (OR = 1.11 [95% CI 0.88-1.39], p interaction = 0.002). 20 
Conclusions and impact: Our results do not provide evidence for an association of higher 21 
CML or lower esRAGE levels with risk of pancreatic cancer. The role of AGE/RAGE in 22 
pancreatic cancer would benefit from further investigations. 23 
24 
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Introduction 1 
Advanced glycation endproducts (AGE) are formed by non-enzymatic reactions of 2 
reduced sugars, such as glucose, with amino groups in proteins, lipids, and nucleic acids. 3 
Exogenous sources of AGE are those derived from tobacco and those from thermally 4 
processed food, so called dietary AGEs, whereas endogenously, AGEs can be formed in a 5 
wide range of body tissues and cell types. The endogenous formation of AGE is slow under 6 
non-pathological conditions but enhanced during hyperglycaemia. One of the most prominent 7 
and also best studied AGE is Nε-(carboxymethyl)lysine (CML), a glycoxidation product (1, 2). 8 
AGEs are thought to exert their pro-inflammatory effects by binding to receptors, with RAGE 9 
being the best characterized (2, 3). In blood, soluble forms of RAGE have been detected, 10 
including splice variants such as the most prominent endogenous secreted RAGE (esRAGE 11 
or RAGEv1, (4)) or cleavage forms of membrane-bound full-length RAGE (5). These soluble 12 
forms of RAGE are suspected to bind free AGEs and, therefore, might act as “decoy 13 
receptors”, preventing RAGE ligands from interaction with cell surface RAGE. Consequently, 14 
this is thought to inhibit angiogenesis and tumour cell activation (6). 15 
AGE and RAGE are expressed in many tissues and cell types (2, 7), and for many 16 
years, both have been implicated in a number of metabolic, neurodegenerative, and 17 
inflammatory diseases such as diabetes mellitus and vascular diseases (8). More recently, 18 
involvement of the AGE/RAGE axis in cancer has been suspected (6, 7, 9, 10). Human 19 
investigations on AGE and RAGE concentrations and their associations with pancreatic 20 
cancer risk are, however, limited. One hospital-based case-control study has shown 21 
decreased levels of soluble RAGE among their 51 pancreatic cancer patients compared to 22 
cancer-free control subjects (11) and a prospective case-cohort study among male Finnish 23 
smokers with 255 cases observed a decrease in risk of pancreatic cancer with elevated 24 
soluble RAGE, whereas CML levels were not related to pancreatic cancer risk (12). Up to 25 
date, no prospective study has been conducted investigating the relationship of the splice 26 
variant esRAGE with risk of pancreatic cancer. 27 
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To elucidate the suspected positive relationship of CML and the suspected inverse 1 
relationship of esRAGE with risk of pancreatic cancer, we conducted a nested case-control 2 
study within the European Prospective Investigation into Cancer and Nutrition (EPIC), using 3 
data from 454 pancreatic cancer subjects and the equal number of cancer-free control 4 
subjects selected from the general western European population. 5 
 6 
7 
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Materials and Methods 1 
 2 
The EPIC cohort 3 
EPIC is a large prospective cohort study with 519,978 participants enrolled between 4 
1992 and 2000 in 23 centres across 10 European countries (Denmark, France, Germany, 5 
Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom). At 6 
baseline, blood was taken and detailed questionnaires were distributed, covering amongst 7 
others habitual diet, anthropometric measures, data on physical activity, socio-economic 8 
status, smoking and medical conditions such as history of diabetes. Study design, 9 
population, and baseline data collection have been described previously in detail (13, 14). 10 
EPIC as well as this individual project were approved by the local ethical review committees 11 
and each study participant provided informed consent. 12 
 13 
Ascertainment of cases and control selection 14 
In all EPIC centres, data on vital status are collected through mortality registries, in 15 
combination with health insurance data (France) or active follow-up (Greece). Population 16 
cancer registries (Denmark, Italy, the Netherlands, Spain, Sweden, and the United Kingdom) 17 
or a combination of methods including insurance records, cancer and pathology registries, 18 
and active follow-up through study subjects (France, Germany, Greece) were used to identify 19 
incident cancer cases. For the present project on pancreatic cancer, closure date of the 20 
study period were defined as the latest date of complete follow-up for both cancer incidence 21 
and vital status in each EPIC centre; varying from December 2002 to December 2005. The 22 
last known contact, the date of diagnosis, or the date of death, whichever came first, were 23 
defined as the end of follow-up in Germany, Greece, and France. 24 
Exocrine pancreatic cancer incident data were coded as C25 (25.0-25.3, 25.7-25.9) 25 
according to ICD-10. Cases were selected among both sexes who developed pancreatic 26 
cancer after their recruitment into the study and before the end of the study period. Exclusion 27 
criteria were occurrence of other malignant tumours preceding pancreatic cancer diagnosis, 28 
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except non-melanoma skin cancer, and non-availability of blood specimens. Follow-up has 1 
led to the identification of 578 primary exocrine pancreatic adenocarcinomas, for 466 of 2 
these blood specimens were available, and for 454 sRAGE and CML could be measured. 3 
Most tumours occurred in the pancreatic head (42%) with few in the body (7%) and tail (5%), 4 
while the rest of the tumours were of unknown localization. 333 (73%) of the pancreatic 5 
cancer cases were microscopically confirmed and the remaining 34% were diagnosed by 6 
physical examination, imaging results, or clinical symptoms. For each case, one control alive 7 
and free of cancer at the time of diagnosis of the case was selected using an incidence 8 
density sampling procedure. Cases and controls were individually matched, using the 9 
following matching criteria: centre, sex, age at blood collection (+/- 3 years), date of blood 10 
donation (+/- 3 months), time of blood donation (+/- 2 hours), fasting status (<3 hours, 3-6 11 
hours, >6 hours after last meal) and, in women, use of hormones (oral contraceptive pill, 12 
hormone or oestrogen replacement therapy). 13 
 14 
Biological samples and laboratory analyses 15 
Blood samples of roughly 420,000 EPIC participants were aliquoted and either stored 16 
in liquid nitrogen (-196°C) at a central biorepository, or locally in freezers at -70°C (Sweden) 17 
or nitrogen vapour (-150°C, Denmark). Serum samples (and EDTA plasma for the Swedish 18 
centre Umea) from one centre were analyzed within the same analytical batch in the 19 
specialized immunoassay laboratory of the Division of Cancer Epidemiology (Heidelberg, 20 
Germany). ELISA was used to measure esRAGE in serum and plasma samples (B-Bridge 21 
International, Inc., Mountain View, CA, USA). Measurements for CML were performed with 22 
ELISA from a different company in serum samples only, after enzymatic pre-treatment with 23 
Proteinase K (Synvista Therapeutics, Inc., Montvale, NJ, USA). Therefore, plasma samples 24 
from Umea were not included in the CML analysis. In total, esRAGE could be measured for 25 
886 subjects and CML for 832 subjects. Intra-batch and inter-batch coefficients of variation 26 
were 2.2 and 5.2% for esRAGE and 10.6 and 19.4% for CML. Units for esRAGE are 27 
expressed as pg/mL and for CML as ng/mL. 28 
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 1 
Statistical analyses 2 
Partial Spearman’s rank correlation coefficients [ρ] adjusted for age, sex, and EPIC 3 
recruitment centre were used to assess the correlations of CML and esRAGE with 4 
anthropometric measures, glycated haemoglobin (HbA1c), age, and other variables of 5 
interest such as dietary factors or inflammatory markers. HbA1c and inflammatory markers 6 
have been measured previously in the same study population and the results on HbA1c have 7 
been published recently (15). 8 
Conditional logistic regression models were applied to estimate odds ratios (OR) and 9 
95% confidence intervals (CI) for the associations of CML and esRAGE with pancreatic 10 
cancer risk, by either modelling the exposure variables continuously or using quintiles. Cut-11 
points for the categories were based on the distribution of controls and trend tests over 12 
quintiles were assessed by modelling the median value within each category as a continuous 13 
variable. Continuous measurements of CML and esRAGE were log-transformed to achieve 14 
approximate normality. To assess the association of bioavailable CML with risk of pancreatic 15 
cancer, we calculated the CML / esRAGE ratio and used this variable in all statistical models 16 
in addition to CML and esRAGE. 17 
Conditional logistic regression was also used to investigate the relationship of potential 18 
confounders with cancer risk, including body mass index (BMI), waist circumference, waist-19 
hip ratio (WHR), dietary factors (daily average intakes of alcohol, total fat, total protein, 20 
carbohydrates, glucose, red meat, processed meat), smoking status (never, former, current, 21 
unknown), physical activity (Cambridge Index (16): active, moderately active, moderately 22 
inactive, inactive), and diabetes. Subjects were classified as diabetics in the current study if 23 
they had baseline HbA1c levels ≥ 6.5% and/or self-reported diabetes at recruitment (n = 93). 24 
Variables were considered as confounders if they were associated with the exposure and the 25 
outcome and if they changed the logistic β-estimate in a multivariate model by more than 26 
10%. We finally adjusted for BMI as a continuous variable and for smoking status 27 
categorically, with the following categories: never smoker; former smoker who stopped less 28 
12 
 
than 10 years ago, former smoker who stopped 10 or more years ago; current smoker with 1-1 
9, 10-19, or ≥ 20 cigarettes per day; and smoking status unknown. In addition, logistic 2 
regression models were mutually adjusted for esRAGE and CML. HbA1c was added in 3 
further models to explore the potential additional confounding effect of progressively 4 
deteriorating glucose tolerance and of diabetes, and to investigate the effect of 5 
hyperglycaemia as an enhancer of AGE-formation.  6 
In addition, analyses were stratified by factors that could modify the relationship 7 
between CML and esRAGE and pancreatic cancer, such as diabetes. Heterogeneity of effect 8 
was assessed by adding cross-product terms into the logistic regression models over 9 
continuous levels of CML and esRAGE and testing the significance with the Wald test, crude 10 
and adjusted for BMI and smoking. 11 
All statistical analyses were conducted using the Statistical Analysis System (SAS) 12 
software package, Version 9.2 (SAS Institute Inc., Cary, North Carolina, USA). All statistical 13 
tests were two-tailed and threshold of significance was 0.05. 14 
 15 
16 
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Results 1 
Pancreatic cancer cases were on average 63 years old and had a mean follow-up time 2 
of 5.3 years (range 0-13; Table 1). At baseline, a higher proportion of cases reported being 3 
diabetic (14 vs. 8%) or current smokers (31 vs. 22%) compared to controls. No case-control 4 
differences by waist-hip ratio were observed among men and women, and no differences by 5 
BMI or waist circumference among men. Female pancreatic cancer cases had higher BMI 6 
and larger waist circumference than female controls. 7 
CML and esRAGE correlated weakly but significantly with each other among controls 8 
(ρ = 0.15 [95% CI 0.04 to 0.24]), and both markers correlated negatively with anthropometric 9 
measures with partial correlation coefficients up to -0.27 (Table 2). Negative correlations 10 
were also observed for esRAGE and CML with inflammatory markers such as C-reactive 11 
protein (CRP, Table 2). Controls with diabetes had lower CML (geometric mean = 689 ng/mL 12 
[95% CI 625-760]) and esRAGE levels (372 pg/mL [321-432]) than non-diabetic controls 13 
(737 [719-755] and 457 [443-437], respectively). CML levels were lowest among current 14 
smokers compared with non-smokers but no differences in esRAGE levels were observed by 15 
smoking status (data not shown). CML and esRAGE levels correlated significantly with daily 16 
average intakes of glucose (Table 2) but not with intakes of total fat, total protein, red meat, 17 
processed meat, or alcohol use (data not shown). 18 
Elevated CML levels tended to be associated with a reduced pancreatic cancer risk 19 
(crude OR = 0.57 [95% CI 0.32-1.01] comparing highest vs. lowest quintile, p-trend = 0.05; 20 
Table 3). Adjustments for smoking, BMI, HbA1c, and esRAGE attenuated the association of 21 
CML with pancreatic cancer risk (OR = 0.78 [95% CI 0.41-1.49], p-trend = 0.483], with BMI 22 
having the strongest effect. By contrast, esRAGE levels were not associated with pancreatic 23 
cancer risk (crude OR = 0.98 [95% CI 0.62-1.54], comparing highest with lowest quintile). 24 
Additional adjustments for inflammatory markers or dietary factors had a negligible effect on 25 
the risk estimates for CML and esRAGE (data not shown). The CML / esRAGE ratio was not 26 
associated with risk of pancreatic cancer (Table 3). 27 
14 
 
The associations of elevated CML and esRAGE levels with pancreatic cancer risk 1 
differed statistically significantly by diabetes and smoking status. The association with 2 
esRAGE was also modified by follow-up time (time between recruitment [blood collection] 3 
and date of tumour diagnosis, Figure 1). In these analyses, never and former smokers 4 
seemed to have a lower and current smokers a higher risk of pancreatic cancer with elevated 5 
CML levels. For higher concentrations of both biomarkers, risk was stronger among diabetic 6 
than among non-diabetic participants. However, none of the risk-estimates were significant in 7 
either crude or adjusted analyses. For higher esRAGE levels, pancreatic cancer risk was 8 
significantly lower by 54% among participants with less than two years of follow-up, which 9 
was slightly stronger after multivariate adjustments, whereas there was no association 10 
among those with a longer follow-up. No heterogeneity of effects was seen by measures of 11 
adiposity, by fasting status, or by median intake of dietary exposures such as red or 12 
processed meat (data not shown). The association between CML and pancreatic cancer risk 13 
did not differ by levels of esRAGE and vice versa (data not shown). 14 
15 
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Discussion 1 
Prospectively, we observed a roughly 40% decrease in pancreatic cancer risk with 2 
elevated CML levels (>1017 vs. <560 ng/L), which disappeared after multivariate 3 
adjustments for HbA1c levels, BMI, smoking status, and esRAGE concentrations. Elevated 4 
esRAGE levels and the CML / esRAGE ratio were not associated with risk of pancreatic 5 
cancer. 6 
RAGE and its ligands have been linked to several diseases, including diabetes and its 7 
complications, chronic inflammatory diseases (8), and more recently, to cancer (6, 7, 9, 10). 8 
Activation of the multiligand/RAGE axis has been shown to perpetuate inflammation at the 9 
tumour microenvironment level, stimulate angiogenesis, and support invasion and metastasis 10 
(10). In particular, the RAGE ligand S100P and RAGE itself have been found to be over-11 
expressed in pancreatic cancer cells or tissue (7). By contrast, overexpression of the splice 12 
variant esRAGE has been shown to inhibit expression of genes involved in tumour formation, 13 
cell invasion, and angiogenesis in various cells (17). However, data on CML and esRAGE 14 
levels in pancreatic cancer cells or plasma are sparse. 15 
Ours is the third prospective study investigating the association of circulating levels of 16 
CML with risk of cancer. Jiao et al. did not detect any associations of CML levels with risk of 17 
colorectal cancer (18), but they observed a decrease in risk of pancreatic cancer in the 18 
unadjusted analyses, which became non-significant in the multivariable model (12). Our 19 
results are in line with the latter, with a borderline inverse association in the crude model. In 20 
contrast to our results of esRAGE, we did not observe any effect modification by follow-up 21 
time. Based on these results and the observation that plasma AGE levels not necessarily 22 
reflect tissue AGE levels (19), plasma levels of CML, and probably also of other AGE, might 23 
be elevated in tumour tissue only, but not in plasma either many years prior to tumour 24 
diagnosis or shortly before its onset. Future studies are needed to clarify this hypothesis as, 25 
to date, no data is available on CML levels in pancreatic tumour tissue and only little is 26 
known on plasma circulating levels preceding cancer diagnosis. 27 
16 
 
The mechanisms by which esRAGE versus RAGE production is regulated are not fully 1 
understood (6). Secretion of esRAGE is a consequence of RAGE mRNA processing, 2 
possibly indicating enhanced RAGE expression through increased extracellular ligand 3 
binding or through intracellular activation of NF-κB secondary to cytokine release. Increasing 4 
esRAGE levels have been postulated to bind AGE and, therefore, prevent the activation of 5 
post-RAGE signalling (20). Targeted knockdown of RAGE in pancreatic tumour cells resulted 6 
in increased apoptosis, diminished autophagy, and decreased tumour cell survival while 7 
overexpression had the opposite effects (21). Lower sRAGE and esRAGE levels in tissue, by 8 
contrast, have been associated with various tumorigenic states (6). Whether plasma levels 9 
reflect tissue levels is not known. But if so, esRAGE (and sRAGE) levels should be 10 
decreased in blood of pancreatic cancer patients. Indeed, this has been observed for sRAGE 11 
in one case-control study (11). In a prospective setting, this should translate into a decrease 12 
in pancreatic cancer risk with higher esRAGE levels, which we did not observe in our study. 13 
However, restricting the analyses to subjects developing pancreatic cancer within the first 14 
two years of follow-up (time between blood collection and tumour diagnosis), a risk 15 
decreasing effect was observed with higher esRAGE levels (OR = 0.46). Whether an 16 
undiagnosed tumour has led to lower esRAGE levels or whether lower esRAGE levels have 17 
been involved in pancreatic tumour development remains unanswered and needs to be 18 
addressed in further prospective studies with a large number of pancreatic cancer cases. 19 
 20 
The overall association of pancreatic cancer risk with increasing CML and esRAGE 21 
levels seemed to be modified by the diabetes status of our subjects, i.e., a rather strong 22 
increase in risk among diabetics and a null-finding among non-diabetic participants. 23 
However, confidence intervals were wide and the test for heterogeneity was no longer 24 
significant after multivariate adjustments for BMI and smoking status. The first implicates low 25 
statistical power and the latter questions the observed effect modification by diabetes status. 26 
A recent population based case-control study found higher blood levels of AGE and an 27 
increased RAGE expression but a decreased esRAGE expression and lower blood levels of 28 
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esRAGE in diabetic than non-diabetic participants (22). Our results are in line with the latter, 1 
i.e. lower esRAGE levels in diabetics. We have no explanation for our findings of lower CML 2 
levels in diabetic participants, as this is in contrast to the above study and also in contrast to 3 
the biological explanation of CML formation. After additional adjustment for HbA1c, ORs for 4 
pancreatic cancer risk with increasing CML and esRAGE levels were further off levels of 5 
significance in our study. Based on these observations, we suspect that elevated glucose 6 
levels and diabetes, but not altered CML and esRAGE levels, are the conditions associated 7 
with pancreatic cancer risk. 8 
Our observed negative correlations of CML with anthropometric indices are in line with 9 
a recent publication (23). Semba et al. proposed biological mechanisms for the correlations 10 
of CML with anthropometry, such that CML might be preferentially stored in fat tissue or 11 
metabolized in adipocytes. As overweight correlates with inflammatory markers, we 12 
suspected that the observed correlations of CML and esRAGE with inflammatory markers 13 
might be confounded by overweight, and, indeed, adjustments for BMI weakened these 14 
correlations. Therefore, the known link between overweight and inflammation might be the 15 
explanation for the observed correlations of CML with inflammatory markers. 16 
 17 
Our study has several limitations. Drawing blood once does not necessarily reflect 18 
long-term levels of AGE products and its soluble receptor and repeated freeze-thaw cycles 19 
such as in our study might affect CML and esRAGE concentrations in serum/plasma. 20 
Moreover, analysing the agents in duplicate was not possible due to limited sample volume. 21 
Analyzing the matched case-control set within one assay, however, reduces to some extent 22 
laboratory measurement error. Matching on several variables bears the risk of overmatching 23 
and thus, may harm statistical efficiency, validity, and/or cost efficiency (24). However, the 24 
chosen variables are either standardization variables (age, sex), reflect the variation in 25 
incidence of pancreatic cancer (study centre) or the differences in exposure levels at one 26 
point in time (fasting), and, therefore, are less likely to have introduced overmatching. If so, 27 
then rather an underestimation of the true risk may have occurred by using fasting status. A 28 
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further limitation of our study is related to available questionnaire data and its impact on 1 
statistical analyses and interpretability of results. An inverse relationship has been observed 2 
between renal capacity and circulating CML and esRAGE concentrations in blood (25). We 3 
had no information on renal function or related diseases and, thus, could not control for this 4 
possible confounder. Our study is the largest with respect to the number of pancreatic cancer 5 
subjects in a prospective setting so far, analyzing the risk relationship of CML and esRAGE 6 
with primary exocrine adenocarcinoma of the pancreas. And it is the first to investigate 7 
esRAGE, as Jiao et al. analyzed sRAGE in their study of male Finnish smokers. sRAGE 8 
resembles membrane-bound full-length RAGE, esRAGE, and other splice variant forms of 9 
RAGE. We decided to measure esRAGE instead of sRAGE, as the first has been shown to 10 
be more stable over time than the latter and, in addition, only esRAGE was found to be 11 
capable of capturing AGE-ligands but not other splice variants such as N-truncated RAGE 12 
(20). Investigating esRAGE in human cells and organs is a new evolving area of research 13 
and only little is known on its impact on diseases and disorders (6, 20, 26). 14 
Future epidemiological studies should analyze several AGE and RAGE derivatives in 15 
blood drawn several times, limit the number of freeze-thaw cycles, and collect additional 16 
health and disease related information such as kidney function or diseases, diabetes, 17 
cardiovascular diseases, or use of therapeutics which may influence circulating blood levels 18 
of AGEs or soluble RAGE derivates. 19 
 20 
Conclusion 21 
In our study conducted among the general western European population, we did not 22 
find a clear association of elevated CML or the endogenous secretory receptor esRAGE with 23 
risk of pancreatic cancer. Because only two prospective studies investigated this relationship 24 
but with different soluble RAGE derivates, and one of them exclusively among male 25 
smokers, further studies are needed to evaluate the potential role of the AGE/RAGE axis 26 
with pancreatic cancer risk. 27 
 28 
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Table 1. Baseline characteristics of pancreatic cancer cases and matched controls 
Variable Cases (n=454) Controls (n=452) 
   
% Women (n) 52 (233) 52 (234) 
Age at recruitment [y], mean (range) 58 (30 – 76) 58 (30 – 76) 
Age at diagnosis [y], mean (range) 63 (37 – 82) - 
Follow-up [y], mean (range) 5.3 (0 – 13) - 
   
BMI [kg/m2], mean ± SD   
     Male 26.8 ± 3.6 26.7 ± 3.7 
     Female 26.5 ± 5.0 25.2 ± 4.3 
Waist-hip ratio, mean ± SD   
     Male 0.95 ± 0.06 0.95 ± 0.06 
     Female 0.82 ± 0.07 0.81 ± 0.06 
Waist circumference [cm], mean ± SD   
     Male 96.3± 9.9 96.7 ± 10.2 
     Female 84.3 ± 12.5 81.2 ± 10.7 
   
Smoking status, n (%)   
     Never 162 (36) 197 (44) 
     Former 144 (32) 150 (33) 
     Current 143 (31) 100 (22) 
     Unknown 5 (1) 5 (1) 
   
Alcohol intake at recruitment [g/d]   
     Male, geometric mean (95% CI) 12 (10-15) 11 (9-14) 
     Female, geometric mean (95% CI) 5 (4-6) 4 (4-5) 
   
Fasting status, n (%)   
     Fasting (≥ 6 hours) 118 (26) 113 (25) 
     In between (3 - 6 hours) 78 (17) 76 (17) 
     Non fasting (< 3 hours) 176 (39) 182 (40) 
     Unknown 82 (18) 81 (18) 
   
Self-reported diabetes at recruitment, n (%) 33 (7) 19 (4) 
Subjects HbA1c ≥ 6.5%, n (%) 54 (12) 29 (6) 
Self-reported diabetes or HbA1c ≥ 6.5%, n (%) 59 (14) 34 (8) 
     Unknown 18 (4) 17 (4) 
   
CML [ng/mL], geometric mean (95% CI) 728 (705-751) 750 (725-775) 
esRAGE [pg/mL], geometric mean (95% CI) 452 (432-473) 454 (435-476) 
CML / esRAGE ratio, geometric mean (95% CI) 1.61 (1.53-1.70) 1.64 (1.55-1.73) 
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Table 2: Partial Spearman’s rank correlation coefficients (95% CI) of CML and esRAGE with covariates, in 
control participants a 
 
Covariate CML esRAGE 
   
esRAGE 0.15 (0.04 to 0.24) - 
   
BMI -0.15 (-0.25 to -0.05) -0.27  (-0.36 to -0.17) 
   
Waist -0.20 (-0.30 to -0.10) -0.22  (-0.32 to -0.12) 
   
WHR -0.23 (-0.32 to -0.13) -0.16  (-0.26 to -0.06) 
   
Smoking status b -0.12 (-0.21 to -0.02) -0.09 (-0.19 to 0.01) 
   
Numbers of cigarettes smoked c -0.07 (-0.30 to 0.17) 0.20 (-0.04 to 0.42) 
   
Time since quitting smoking d 0.12 (-0.06 to 0.29) 0.19 (0.01 to 0.36) 
   
Fasting status e -0.10 (-0.21 to 0.01) -0.04 (-0.15 to 0.07) 
   
Diabetes status f -0.12 (-0.22 to -0.02) -0.12 (-0.22 to -0.02) 
   
HbA1c -0.07 (-0.18 to 0.03) -0.09  (-0.19 to 0.02) 
   
Adiponectin 0.21 (0.11 to 0.31) 0.16 (0.06 to 0.26) 
   
CRP -0.26 (-0.36 to -0.16) -0.22  (-0.32 to -0.11) 
   
IL-6 -0.13 (-0.24 to -0.03) -0.16  (-0.26 to -0.05) 
   
Dietary glucose 0.18 (0.08 to 0.28) 0.12 (0.02 to 0.22) 
   
Processed meat -0.01 (-0.11 to 0.09) -0.07 (-0.17 to 0.03) 
   
 
a Partial Spearman’s rank correlation coefficients [ρ] adjusted for age, sex and EPIC recruitment centre. CML and 
esRAGE levels were log transformed to achieve normality. 
b Never, former, current smoker 
c Among current smokers 
d Among former smokers 
e Non-fasting (<3 hours), in between (3-6 hours), fasting (>6 hours after last meal) 
f Non-diabetics, diabetics (self-reported diabetes at recruitment baseline and/or HbA1c levels ≥ 6.5%) 
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Table 3. Relative risk [OR (95% CI)] of pancreatic cancer by quintiles of CML and esRAGE 
  Quintiles a Ρ OR for a doubling 
  1 2 3 4 5 trend b in concentration 
         
CML Quartile cut-offs [ng/L] 328 - 559 560 - 680 681 - 817 818 - 1017 1018 - 1819   
 No. cases / controls 86 / 82 99 / 83 88 / 82 74 / 83 65 / 82   
 Model 1c 1.0 1.09 (0.70-1.69) 0.92 (0.57-1.50) 0.70 (0.42-1.18) 0.57 (0.32-1.01) 0.05 0.70 (0.48-1.02) 
 Model 2d 1.0 1.14 (0.72-1.80) 1.13 (0.68-1.87) 0.87 (0.50-1.50) 0.77 (0.42-1.41) 0.4 0.85 (0.57-1.28) 
 Model 3e 1.0 1.19 (0.75-1.88) 1.22 (0.73-2.06) 0.88 (0.50-1.55) 0.79 (0.42-1.46) 0.5 0.88 (0.59-1.33) 
 Model 4r 1.0 1.10 (0.68-1.78) 1.20 (0.71-2.05) 0.82 (0.46-1.46) 0.78 (0.41-1.49) 0.5 0.86 (0.56-1.32) 
         
esRAGE Quartile cut-offs [pg/ml] 109 - 308 309 - 401 402 - 521 522 - 671 672 - 1793   
 No. cases / controls 89 / 86 88 / 86 85 / 87 81 / 86 88 / 86   
 Model 1c 1.0 0.98 (0.63-1.51) 0.93 (0.60-1.46) 0.90 (0.57-1.41) 0.98 (0.62-1.54) 0.9 0.98 (0.80-1.21) 
 Model 2d 1.0 1.02 (0.65-1.60) 0.94 (0.59-1.50) 0.96 (0.60-1.55) 1.09 (0.67-1.78) 0.7 1.04 (0.83-1.30) 
 Model 3e 1.0 1.08 (0.68-1.72) 1.02 (0.63-1.66) 1.15 (0.70-1.88) 1.18 (0.71-1.94) 0.5 1.12 (0.88-1.41) 
 Model 4r 1.0 0.97 (0.59-1.59) 1.11 (0.66-1.85) 1.25 (0.74-2.11) 1.14 (0.67-1.94) 0.4 1.13 (0.88-1.45) 
         
Ratio Quartile cut-offs [pg/ml] 0.34 - 1.03 1.04 - 1.43 1.43 - 1.92 1.95 - 2.65 2.66 - 7.55   
 No. cases / controls 82 / 79 77 / 79 91 / 80 75 / 79 71 / 79   
 Model 1c 1.0 0.95 (0.60-1.50) 1.12 (0.70-1.79) 0.89 (0.55-1.43) 0.83 (0.50-1.36) 0.4 0.94 (0.77-1.16) 
 Model 2d 1.0 0.87 (0.53-1.41) 1.03 (0.63-1.68) 0.86 (0.52-1.43) 0.80 (0.48-1.36) 0.4 0.94 (0.75-1.17) 
 Model 3e 1.0 0.90 (0.55-1.48) 1.01 (0.60-1.69) 0.81 (0.48-1.36) 0.71 (0.41-1.22) 0.2 0.88 (0.70-1.10) 
         
 
a Quintile cut points were based on the distribution of controls. 
b P trend test was based on median values of each quartile. 
c Model 1: Crude OR based on logistic regression conditioned on matching factors (sex, age, date and time of blood donation, fasting status, and use of 
hormones). 
d Model 2: OR adjusted for smoking and BMI. 
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e Model 3: As in model 2 and additionally adjusted for levels of HbA1c. 
f Model 4: As in model 3 and additionally adjusted for levels of esRAGE (for CML) or CML (for esRAGE). 
CI = confidence interval, No. = number, CML and esRAGE concentrations on continuous scale were log transformed to achieve normality, smaller number of 
subjects due to missing laboratory values. 
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Legends of Tables and Figures 
 
Table 1. Baseline characteristics of pancreatic cancer cases and matched controls 
 
Table 2: Partial Spearman’s rank correlation coefficients (95% CI) of CML and esRAGE with 
covariates, among pancreatic cancer cases and control subjects 
 
Table 3. Relative risk [OR (95% CI)] of pancreatic cancer by quintiles of CML and esRAGE 
 
Figure 1: Relative risks [OR (95% CI)] of pancreatic cancer for a doubling in CML and 
esRAGE concentrations, all and stratified by diabetes and smoking status, and by length of 
follow-up (≤ vs. > 2yrs) 


